(248 days)
Not Found
No
The 510(k) summary describes a physical implant (a fusion cage) and its mechanical testing. There is no mention of software, algorithms, or any capabilities that would suggest the use of AI or ML.
Yes
This device is a medical implant designed to facilitate intervertebral body fusion in the cervical spine for patients with degenerative disc disease, which is a therapeutic intervention.
No
The device is an interbody fusion cage system used for treatment, not for diagnosing a condition. It is a therapy device.
No
The device description explicitly states that the device is an "Anterior Cervical Interbody Fusion Cage system" made of physical materials (PEEK-OPTIMA LT1, Evonik VESTAKEEP i4R, Tantalum marker pins, or titanium alloy) and is intended for surgical implantation. This is a hardware medical device, not software only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Description and Intended Use: The MATISSE Anterior Cervical Interbody Fusion Cage system is a physical implant designed to be surgically placed in the cervical spine to facilitate bone fusion. It is a medical device used in vivo (within the body), not a test performed in vitro (outside the body).
- Lack of IVD Characteristics: The description does not mention any analysis of biological samples, diagnostic testing, or any of the typical components or processes associated with IVDs.
Therefore, the MATISSE Anterior Cervical Interbody Fusion Cage system is a surgical implant, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
MATISSE Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MATISSE Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C3 to C7 disc levels using autograft bone. MATISSE Anterior Cervical Interbody Fusion Cage system is to be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage.
The MATISSE Anterior Cervical Interbody Fusion Cage system is intended for use as an interbody fusion cage device to maintain cervical intervertebral spacing and must be used with supplemental fixation systems that have been cleared for use in the cervical spine.
Product codes (comma separated list FDA assigned to the subject device)
ODP
Device Description
The MATISSE Anterior Cervical Interbody Fusion Cage system is intended for use as an interbody fusion cage device to maintain cervical intervertebral spacing and must be used with supplemental fixation systems that have been cleared for use in the cervical spine. The devices are available in a variety of different sizes and configurations to accommodate anatomical variation in different vertebral levels and/or patient anatomy. The devices are made of either PEEK-OPTIMA LT1 or Evonik VESTAKEEP i4R, with Tantalum marker pins, or titanium alloy.
The MATISSE Anterior Cervical Interbody Fusion Cage System consists of PEEK with marker pins made of Tantalum as well as Titanium, both of which are identical to its predicate device. All of the heights, lengths, and widths are within range covered by its predicate device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
cervical spine, C3 to C7 disc levels
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The MATISSE Anterior Cervical Interbody Fusion Cage System device underwent Finite Element Analysis ("FEA"), static and dynamic axial compression testing and confirmatory static axial compression testing according to ASTM F2077, expulsion testing, and subsidence testing according to ASTM F2267. The results met all acceptance criteria and demonstrate that the MATISSE Anterior Cervical Interbody Fusion Cage System does not raise concerns regarding safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of three human profiles facing right, arranged in a stacked formation. The profiles are rendered in a dark color, creating a silhouette effect. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the top half of the logo.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 1, 2017
CTL Medical Corporation % Mr. Paul Speidel Senior Regulatory/Quality Consultant ROMIS, Inc. 110 Haverhill Road, Suite 526 Amesbury, Massachusetts 01913
Re: K162682
Trade/Device Name: MATISSE Anterior Cervical Interbody Fusion Cage System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: ODP Dated: May 26, 2017 Received: May 30, 2017
Dear Mr. Speidel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K162682
Device Name
MATISSE Anterior Cervical Interbody Fusion Cage System
Indications for Use (Describe)
MATISSE Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MATISSE Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C3 to C7 disc levels using autograft bone. MATISSE Anterior Cervical Interbody Fusion Cage system is to be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage.
Type of Use (Select one or both, as applicable)
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------------------ | ----------------------------------------------- |
|X | Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
CTL Medical Corporation's MATISSE Anterior Cervical Interbody Fusion Cage System
| Submitter | CTL Medical Corporation
Tosan Onosode
4550 Excel Parkway Suite 300
Addison, TX 75001 |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| | Phone: 214-545-5820
Fax: 888-831-4892 |
| Contact Person: | Paul Speidel
RQMIS, Inc.
110 Haverhill Road, Suite 526
Amesbury, MA 01913
Phone: 978-358-7307 |
Date Prepared: May 26, 2017
| Name of Device | MATISSE Anterior Cervical
Interbody Fusion Cage System |
|--------------------------|-----------------------------------------------------------------------------------------------|
| Name/Address of Sponsor: | CTL Medical Corporation
Toson Onosode
4550 Excel Parkway Suite 300
Addison, TX 75001 |
Common or Usual Name
Intervertebral Body Fusion Device
Classification Name
Intervertebral Body Fusion Device, Cervical (Product Code ODP)
Class
Class II
4
Classification Number
21 CFR 888.3080
Predicate Device
K121569, MATISSE Anterior Cervical Interbody Fusion Cage System
Device Description
Indications for Use:
MATISSE Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MATISSE Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C3 to C7 disc levels using autograft bone. MATISSE Anterior Cervical Interbody Fusion Cage system is to be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage.
Intended Use:
The MATISSE Anterior Cervical Interbody Fusion Cage system is intended for use as an interbody fusion cage device to maintain cervical intervertebral spacing and must be used with supplemental fixation systems that have been cleared for use in the cervical spine. The devices are available in a variety of different sizes and configurations to accommodate anatomical variation in different vertebral levels and/or patient anatomy. The devices are made of either PEEK-OPTIMA LT1 or Evonik VESTAKEEP i4R, with Tantalum marker pins, or titanium alloy.
Technological Characteristics
The MATISSE Anterior Cervical Interbody Fusion Cage System consists of PEEK with marker pins made of Tantalum as well as Titanium, both of which are identical to its predicate device. All of the heights, lengths, and widths are within range covered by its predicate device.
Performance Data
The MATISSE Anterior Cervical Interbody Fusion Cage System device underwent Finite Element Analysis ("FEA"), static and dynamic axial compression testing and confirmatory static axial compression testing according to ASTM F2077, expulsion testing, and subsidence testing according to ASTM F2267. The
5
results met all acceptance criteria and demonstrate that the MATISSE Anterior Cervical Interbody Fusion Cage System does not raise concerns regarding safety and effectiveness.
Conclusion
The MATISSE Anterior Cervical Interbody Fusion Cage System is as safe and effective as the predicate MATISSE Anterior Cervical Interbody Fusion Cage System (K121569). The MATISSE Anterior Cervical Interbody Fusion Cage System has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. The minor technological differences between the MATISSE Anterior Cervical Interbody Fusion Cage System and its predicate device raise no new issues of safety or effectiveness. Thus, the MATISSE Anterior Cervical Interbody Fusion Cage System is substantially equivalent.